On April 3, 2026, the Trump administration released its long-awaited budget request for fiscal year 2027 — months past the statutory February deadline and arriving at a moment of significant pressure on the federal health research infrastructure. The document merits careful reading, particularly for those tracking women’s health.
The Headline Numbers
The administration proposes $111.1 billion for the U.S. Department of Health and Human Services — a reduction of $15.8 billion, representing more than a 12 percent cut from the FY2026 enacted level. The proposed $5 billion reduction to the National Institutes of Health is among the most consequential elements, given the agency’s decades-long, bipartisan role as the cornerstone of American biomedical innovation.
Also on the chopping block: the National Institute on Minority Health and Health Disparities (NIMHD), the Fogarty International Center (FIC), and the National Center for Complementary and Integrative Health (NCCIH). The elimination of NIMHD alone would represent a significant step backward from the principle that health equity research is not optional — it is foundational.
The Agency for Healthcare Research and Quality (AHRQ), which provides the evidence base that clinicians and policymakers rely on to make decisions about care quality and patient safety, faces cuts of more than one-third.
The Silence on Women’s Health
Here is what the budget document does not do: it does not mention women’s health research in any substantive way.
The NIH’s Office of Research on Women’s Health (ORWH) appears in the budget appendix as a line item, but with no additional context, no stated priorities, and no signal of the administration’s intentions. For a platform built on the belief that what is omitted matters as much as what is included — this silence is telling.
Women represent more than half the U.S. population. They are diagnosed with autoimmune diseases at disproportionate rates, face a persistent maternal mortality crisis, remain underrepresented in clinical trials, and experience heart disease, Alzheimer’s, and dozens of other conditions differently than men. Research that ignores these sex differences does not just fail women — it fails the integrity of the science itself.
The MAHA Agenda
The budget does prioritize initiatives associated with the Make America Healthy Again (MAHA) agenda, allocating funds toward nutrition services and preventive care. Whether these commitments translate into meaningful women’s health benefit will depend entirely on whether the science underpinning them reflects the full diversity of the population — including women, women of color, and women in rural and underserved communities.
Preventive care without sex-disaggregated data is not prevention. It is assumption dressed as medicine.
What Comes Next
The president’s budget is not law. Congress controls appropriations, and the bipartisan support for NIH funding has historically survived executive branch budget requests that sought to cut it. But the signal matters — particularly for research institutions, investigators, and grant applicants who make decisions based on what they believe funding environments will look like over the next several years.
Organizations like the Society for Women’s Health Research have already urged Congress to reject the proposed cuts and reaffirm support for sustained investment in women’s health research. That pressure must be sustained, and it must be specific: maintaining the ORWH, preserving NIMHD, and ensuring that any MAHA-aligned research priorities are held to the same evidence standards as every other NIH program.
The budget is a political document as much as a fiscal one. Women’s health advocates understand this — and they know that political documents respond to political pressure. The question is whether that pressure will be organized, sustained, and loud enough.
DWHC will continue to monitor budget developments and publish updates as additional documents are released.
